The genetic blueprint of major depressive disorder: Contributions of imaging genetics studies

World Journal of Biological Psychiatry

Volumn 12, Issue 7, 2011, Pages 474-488

  Scharinger, Christian ^a   Rabl, Ulrich ^a   Pezawas, Lukas ^a   Kasper, Siegfried ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

5 HT1A receptor; amygdala; cingulate gyrus; genetics; hippocampus; Major depressive disorder; pharmacogenetics

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; ANTIDEPRESSANT AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; CARBON 11; ESCITALOPRAM; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; RADIOLIGAND; SEROTONIN 1A RECEPTOR; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; TRYPTOPHAN HYDROXYLASE 2;

AMYGDALOID NUCLEUS; BRAIN; BRAIN SIZE; CINGULATE GYRUS; ELECTROCONVULSIVE THERAPY; GENETIC ANALYSIS; GENETIC LINKAGE; GENETIC POLYMORPHISM; GENETIC RISK; HIPPOCAMPUS; HUMAN; MAJOR DEPRESSION; MENTAL DISEASE; NEUROBIOLOGY; NEUROIMAGING; NEUROTRANSMISSION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PHARMACOGENETICS; PHENOTYPE; POSITRON EMISSION TOMOGRAPHY; PROMOTER REGION; PSYCHOPHARMACOLOGY; RECEPTOR BINDING; RECEPTOR DOWN REGULATION; RECEPTOR GENE; REVIEW; SEROTONINERGIC SYSTEM; SINGLE NUCLEOTIDE POLYMORPHISM;

DEPRESSIVE DISORDER, MAJOR; HUMANS; NEUROIMAGING;

EID: 80054865226     PISSN: 15622975     EISSN: 18141412     Source Type: Journal    
DOI: 10.3109/15622975.2011.596220     Document Type: Review

References (197)

1. Adkins DE, Aberg K, McClay JL, Hettema JM, Kornstein SG, Bukszar J, et al. 2010. A genomewide association study of citalopram response in major depressive disorder-a psychometric approach. Biol Psychiatry 68(6):25-27.
2. Akimova E, Lanzenberger R, Kasper S. 2009. The serotonin-1A receptor in anxiety disorders. Biol Psychiatry 66(7):627-635.
3. Alia-Klein N, Goldstein RZ, Kriplani A, Logan J, Tomasi D, Williams B, et al. 2008. Brain monoamine oxidase A activity predicts trait aggression. J Neurosci 28(19):5099-5104.
4. Anand A, Li Y, Wang Y, Wu J, Gao S, Bukhari L, Mathews VP, et al. 2005a. Activity and connectivity of brain mood regulating circuit in depression: a functional magnetic resonance study. Biol Psychiatry 57(10):1079-1088.
5. Anand A, Li Y, Wang Y, Wu J, Gao S, Bukhari L, et al. 2005b. Antidepressant effect on connectivity of the mood-regulating circuit: an FMRI study. Neuropsychopharmacology 30(7):1334-1344.
6. Anand A, Li Y, Wang Y, Gardner K, Lowe MJ. 2007. Reciprocal effects of antidepressant treatment on activity and connectivity of the mood regulating circuit: an FMRI study. J Neuropsychiatry Clin Neurosci 19(3):274-282.
7. Ansorge MS, Zhou M, Lira A, Hen R, Gingrich JA. 2004. Early-life blockade of the 5-HT transporter alters emotional behavior in adult mice. Science 306(5697):879-881.
8. American Psychiatric Association. 2000. Diagnostic and statistical manual of mental disorders. 4th ed. Text revision. Washington, DC: American Psychiatric Association.
9. Arce E, Simmons AN, Lovero KL, Stein MB, Paulus MP. 2008. Escitalopram effects on insula and amygdala BOLD activation during emotional processing. Psychopharmacology (Berlin) 196(4):661-672.
10. Baare WF, Vinberg M, Knudsen GM, Paulson OB, Langkilde AR, Jernigan TL, et al. 2010. Hippocampal volume changes in healthy subjects at risk of unipolar depression. J Psychiatr Res, in press.
11. Bach-Mizrachi H, Underwood MD, Kassir SA, Bakalian MJ, Sibille E, Tamir H, et al. 2006. Neuronal tryptophan hydroxylase mRNA expression in the human dorsal and median raphe nuclei: major depression and suicide. Neuropsychopharmacology 31(4):814-824.
12. Bauer M, Bschor T, Pfennig A, Whybrow PC, Angst J, Versiani M, et al. 2007. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders in Primary Care. World J Biol Psychiatry 8(2):67-104.
13. Bertolino A, Arciero G, Rubino V, Latorre V, De Candia M, Mazzola V, et al. 2005. Variation of human amygdala response during threatening stimuli as a function of 5′HTTLPR genotype and personality style. Biol Psychiatry 57(12):1517-1525.
14. Bhagwagar Z, Rabiner EA, Sargent PA, Grasby PM, Cowen PJ. 2004. Persistent reduction in brain serotonin1A receptor binding in recovered depressed men measured by positron emission tomography with [11C]WAY-100635. Mol Psychiatry 9(4):386-392.
15. Bigos KL, Weinberger DR. 2010. Imaging genetics-days of future past. Neuroimage 53(3):804-809.
16. Birbaumer N, Grodd W, Diedrich O, Klose U, Erb M, Lotze M, et al. 1998. fMRI reveals amygdala activation to human faces in social phobics. NeuroReport 9:1223-1226.
17. Bocchio-Chiavetto L, Bagnardi V, Zanardini R, Molteni R, Nielsen MG, Placentino A, et al. 2010. Serum and plasma BDNF levels in major depression: a replication study and meta-analyses. World J Biol Psychiatry 11(6):763-773.
18. Borg J, Henningsson S, Saijo T, Inoue M, Bah J, Westberg L, et al. 2009. Serotonin transporter genotype is associated with cognitive performance but not regional 5-HT1A receptor binding in humans. Int J Neuropsychopharmacol 12(6):783-792.
19. Bradley SL, Dodelzon K, Sandhu HK, Philibert RA. 2005. Relationship of serotonin transporter gene polymorphisms and haplotypes to mRNA transcription. Am J Med Genet B Neuropsychiatr Genet 136B(1):58-61.
20. Brown SM, Peet E, Manuck SB, Williamson DE, Dahl RE, Ferrell RE, et al. 2005. A regulatory variant of the human tryptophan hydroxylase-2 gene biases amygdala reactivity. Mol Psychiatry 10(9):884-888, 805.
21. Buckholtz JW, Callicott JH, Kolachana B, Hariri AR, Goldberg TE, Genderson M, et al. 2008. Genetic variation in MAOA modulates ventromedial prefrontal circuitry mediating individual differences in human personality. Mol Psychiatry 13(3):313-324.
22. Bueller JA, Aftab M, Sen S, Gomez-Hassan D, Burmeister M, Zubieta JK. 2006. BDNF Val66Met allele is associated with reduced hippocampal volume in healthy subjects. Biol Psychiatry 59(9):812-815.
23. Canli T, Lesch KP. 2007. Long story short: the serotonin transporter in emotion regulation and social cognition. Nat Neurosci 10(9):1103-1109.
24. Canli T, Congdon E, Gutknecht L, Constable RT, Lesch KP. 2005a. Amygdala responsiveness is modulated by tryptophan hydroxylase-2 gene variation. J Neural Transm 112(11):1479-1485.
25. Canli T, Omura K, Haas BW, Fallgatter A, Constable RT, Lesch KP. 2005b. Beyond affect: a role for genetic variation of the serotonin transporter in neural activation during a cognitive attention task. Proc Natl Acad Sci USA 102(34):12224-12229.
26. Canli T, Qiu M, Omura K, Congdon E, Haas BW, Amin Z, et al. 2006. Neural correlates of epigenesis. Proc Natl Acad Sci USA 103(43):16033-16038.
27. Caspi A, McClay J, Moffitt TE, Mill J, Martin J, Craig IW, et al. 2002. Role of genotype in the cycle of violence in maltreated children. Science 297(5582):851-854.
28. Caspi A, Sugden K, Moffitt TE, Taylor A, Craig IW, Harrington H, et al. 2003. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 301(5631):386-389.
29. Caspi A, Hariri AR, Holmes A, Uher R, Moffitt TE. 2010. Genetic sensitivity to the environment: the case of the serotonin transporter gene and its implications for studying complex diseases and traits. Am J Psychiatry 167(5):509-527.
30. Cerasa A, Gioia MC, Labate A, Lanza P, Magariello A, Muglia M, et al. 2008. MAO A VNTR polymorphism and variation in human morphology: a VBM study. Neuroreport 19(11):1107-1110.
31. Chakrabarti S, Grover S, Rajagopal R. 2010. Electroconvulsive therapy: a review of knowledge, experience and attitudes of patients concerning the treatment. World J Biol Psychiatry 11(3):525-537.
32. Chen CH, Suckling J, Ooi C, Fu CH, Williams SC, Walsh ND, et al. 2008a. Functional coupling of the amygdala in depressed patients treated with antidepressant medication. Neuropsychopharmacology 33(8):1909-1918.
33. Chen L, Lawlor DA, Lewis SJ, Yuan W, Abdollahi MR, Timpson NJ, et al. 2008b. Genetic association study of BDNF in depression: finding from two cohort studies and a meta-analysis. Am J Med Genet B Neuropsychiatr Genet 147B(6):814-821.
34. Chen MC, Hamilton JP, Gotlib IH. 2010. Decreased hippocampal volume in healthy girls at risk of depression. Arch Gen Psychiatry 67(3):270-276.
35. Chepenik LG, Fredericks C, Papademetris X, Spencer L, Lacadie C, Wang F, et al. 2009. Effects of the brain-derived neurotrophic growth factor val66met variation on hippocampus morphology in bipolar disorder. Neuropsychopharmacology 34(4):944-951.
36. Chiao JY, Blizinsky KD. 2010. Culture-gene coevolution of individualism-collectivism and the serotonin transporter gene. Proc Biol Sci 277(1681):529-537.
37. Cichon S, Craddock N, Daly M, Faraone SV, Gejman PV, Kelsoe J, et al. 2009. Genomewide association studies: history, rationale, and prospects for psychiatric disorders. Am J Psychiatry 166(5):540-556.
38. Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JP, Churchill R, et al. 2009. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 373(9665):746-758.
39. Clarke H, Flint J, Attwood AS, Munafo MR. 2010. Association of the 5-HTTLPR genotype and unipolar depression: a meta-analysis. Psychol Med 40(11):1767-1778.
40. Costafreda SG, Brammer MJ, David AS, Fu CH. 2008. Predictors of amygdala activation during the processing of emotional stimuli: a meta-analysis of 385 PET and fMRI studies. Brain Res Rev 58(1):57-70.
41. Cremers HR, Demenescu LR, Aleman A, Renken R, van Tol MJ, van der Wee NJ, et al. 2010. Neuroticism modulates amygdala-prefrontal connectivity in response to negative emotional facial expressions. Neuroimage 49(1):963-970.
42. Czeh B, Michaelis T, Watanabe T, Frahm J, de Biurrunm, G, van Kampen M. et al. 2001. Stress-induced changes in cerebral metabolites, hippocampal volume, and cell proliferation are prevented by antidepressant treatment with tianeptine. Proc Natl Acad Sci USA 98(22):12796-12801.
43. Dannlowski U, Ohrmann P, Bauer J, Kugel H, Baune BT, Hohoff C, et al. 2007. Serotonergic genes modulate amygdala activity in major depression. Genes Brain Behav 6(7):672-676.
44. Dannlowski U, Ohrmann P, Bauer J, Deckert J, Hohoff C, Kugel H, et al. 2008. 5-HTTLPR biases amygdala activity in response to masked facial expressions in major depression. Neuropsychopharmacology 33(2):418-424.
45. Dannlowski U, Konrad C, Kugel H, Zwitserlood P, Domschke K, Schoning S, et al. 2009a. Emotion specific modulation of automatic amygdala responses by 5-HTTLPR genotype. Neuroimage 53(3):893-898.
46. Dannlowski U, Ohrmann P, Konrad C, Domschke K, Bauer J, Kugel H, et al. 2009b. Reduced amygdala-prefrontal coupling in major depression: association with MAOA genotype and illness severity. Int J Neuropsychopharmacol 12(1):11-22.
47. David SP, Murthy NV, Rabiner EA, Munafo MR, Johnstone EC, Jacob R, et al. 2005. A functional genetic variation of the serotonin (5-HT) transporter affects 5-HT1A receptor binding in humans. J Neurosci 25(10):2586-2590.
48. Della Pasqua O, Santen GW, Danhof M. 2010. The missing link between clinical endpoints and drug targets in depression. Trends Pharmacol Sci 31(4):144-152.
49. Demirkan A, Penninx BW, Hek K, Wray NR, Amin N, Aulchenko YS, et al. 2010. Genetic risk profiles for depression and anxiety in adult and elderly cohorts. Mol Psychiatry 16(7):773-783.
50. Drevets WC, Frank E, Price JC, Kupfer DJ, Holt D, Greer PJ, et al. 1999. PET imaging of serotonin 1A receptor binding in depression. Biol Psychiatry 46(10):1375-1387.
51. Drevets WC, Bogers W, Raichle ME. 2002. Functional anatomical correlates of antidepressant drug treatment assessed using PET measures of regional glucose metabolism. Eur Neuropsychopharmacol 12(6):527-544.
52. Drevets WC, Thase ME, Moses-Kolko EL, Price J, Frank E, Kupfer DJ, et al. 2007. Serotonin-1A receptor imaging in recurrent depression: replication and literature review. Nucl Med Biol 34(7):865-877.
53. Drevets WC, Savitz J, Trimble M. 2008. The subgenual anterior cingulate cortex in mood disorders. CNS Spectr 13(8):663-81.
54. Egan MF, Kojima M, Callicott JH, Goldberg TE, Kolachana BS, Bertolino A, et al. 2003. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 112(2):257-269.
55. Eker C, Gonul AS. 2010. Volumetric MRI studies of the hippocampus in major depressive disorder: Meanings of inconsistency and directions for future research. World J Biol Psychiatry 11(1):19-35.
56. Fakra E, Hyde LW, Gorka A, Fisher PM, Munoz KE, Kimak M, et al. 2009. Effects of HTR1A C(-1019)G on amygdala reactivity and trait anxiety. Arch Gen Psychiatry 66(1):33-40.
57. Fisher PM, Meltzer CC, Ziolko SK, Price JC, Moses-Kolko EL, Berga SL, et al. 2006. Capacity for 5-HT1A-mediated autoregulation predicts amygdala reactivity. Nat Neurosci 9(11):1362-1363.
58. Fowler JS, Alia-Klein N, Kriplani A, Logan J, Williams B, Zhu W, et al. 2007. Evidence that brain MAO A activity does not correspond to MAO A genotype in healthy male subjects. Biol Psychiatry 62(4):355-358.
59. Friedel E, Schlagenhauf F, Sterzer P, Park SQ, Bermpohl F, Strohle A, et al. 2009. 5-HTT genotype effect on prefrontal-amygdala coupling differs between major depression and controls. Psychopharmacology (Berlin) 205(2):261-271.
60. Frodl T, Meisenzahl EM, Zill P, Baghai T, Rujescu D, Leinsinger G, et al. 2004. Reduced hippocampal volumes associated with the long variant of the serotonin transporter polymorphism in major depression. Arch Gen Psychiatry 61(2):177-183.
61. Frodl T, Schule C, Schmitt G, Born C, Baghai T, Zill P, et al. 2007. Association of the brain-derived neurotrophic factor Val66Met polymorphism with reduced hippocampal volumes in major depression. Arch Gen Psychiatry 64(4):410-416.
62. Frodl T, Koutsouleris N, Bottlender R, Born C, Jager M, Morgenthaler M, et al. 2008a. Reduced gray matter brain volumes are associated with variants of the serotonin transporter gene in major depression. Mol Psychiatry 13(12):1093-1101.
63. Frodl T, Zill P, Baghai T, Schule C, Rupprecht R, Zetzsche T, et al. 2008b. Reduced hippocampal volumes associated with the long variant of the tri- and diallelic serotonin transporter polymorphism in major depression. Am J Med Genet B Neuropsychiatr Genet 147B(7):1003-1007.
64. Frodl T, Reinhold E, Koutsouleris N, Donohoe G, Bondy B, Reiser M, et al. 2010. Childhood stress, serotonin transporter gene and brain structures in major depression. Neuropsychopharmacology 35(6):1383-1390.
65. Frustaci A, Pozzi G, Gianfagna F, Manzoli L, Boccia S. 2008. Meta-analysis of the brain-derived neurotrophic factor gene (BDNF) Val66Met polymorphism in anxiety disorders and anxiety-related personality traits. Neuropsychobiology 58(3-4):163-170.
66. Fu CH, Williams SC, Cleare AJ, Brammer MJ, Walsh ND, Kim J, et al. 2004. Attenuation of the neural response to sad faces in major depression by antidepressant treatment: a prospective, event-related functional magnetic resonance imaging study. Arch Gen Psychiatry 61(9):877-889.
67. Fusar-Poli P, Placentino A, Carletti F, Landi P, Allen P, Surguladze S, et al. 2009. Functional atlas of emotional faces processing: a voxel-based meta-analysis of 105 functional magnetic resonance imaging studies. J Psychiatry Neurosci 34(6):418-432.
68. Garriock HA, Kraft JB, Shyn SI, Peters EJ, Yokoyama JS, Jenkins GD, et al. 2010. A genomewide association study of citalopram response in major depressive disorder. Biol Psychiatry 67(2):133-138.
69. Gasic GP, Smoller JW, Perlis RH, Sun M, Lee S, Kim BW, et al. 2009. BDNF, relative preference, and reward circuitry responses to emotional communication. Am J Med Genet B Neuropsychiatr Genet 150B(6):762-781.
70. Gaspar P, Cases O, Maroteaux L. 2003. The developmental role of serotonin: news from mouse molecular genetics. Nat Rev Neurosci 4(12):1002-1012.
71. Gillihan SJ, Rao H, Wang J, Detre JA, Breland J, Sankoorikal GM, et al. 2010. Serotonin transporter genotype modulates amygdala activity during mood regulation. Soc Cogn Affect Neurosci 5(1):1-10.
72. Gonul AS, Kitis O, Eker MC, Eker OD, Ozan E, Coburn K. 2010. Association of the brain-derived neurotrophic factor Val66Met polymorphism with hippocampus volumes in drug-free depressed patients. World J Biol Psychiatry 12(2):110-118.
73. Gottesman II, Gould TD. 2003. "The endophenotype concept in psychiatry: etymology and strategic intentions." Am J Psychiatry 160(4):636-645.
74. Green EK, Grozeva D, Jones I, Jones L, Kirov G, Caesar S. 2010. The bipolar disorder risk allele at CACNA1C also confers risk of recurrent major depression and of schizophrenia. Mol Psychiatry 15(10):1016-1022.
75. Groves JO. 2007. Is it time to reassess the BDNF hypothesis of depression? Mol Psychiatry 12(12):1079-1088.
76. Gutknecht L, Jacob C, Strobel A, Kriegebaum C, Muller J, Zeng Y, et al. 2007. Tryptophan hydroxylase-2 gene variation influences personality traits and disorders related to emotional dysregulation. Int J Neuropsychopharmacol 10(3):309-320.
77. Haghighi F, Bach-Mizrachi H, Huang YY, Arango V, Shi S, Dwork AJ, et al. 2008. Genetic architecture of the human tryptophan hydroxylase 2 Gene: existence of neural isoforms and relevance for major depression. Mol Psychiatry 13(8):813-820.
78. Hamilton JP, Siemer M, Gotlib IH. 2008. Amygdala volume in major depressive disorder: a meta-analysis of magnetic resonance imaging studies. Mol Psychiatry 13(11):993-1000.
79. Hariri AR, Mattay VS, Tessitore A, Kolachana B, Fera F, Goldman D, et al. 2002. Serotonin transporter genetic variation and the response of the human amygdala. Science 297(5580):400-403.
80. Hariri AR, Goldberg TE, Mattay VS, Kolachana BS, Callicott JH, Egan MF, et al. 2003. Brain-derived neurotrophic factor val66met polymorphism affects human memory-related hippocampal activity and predicts memory performance. J Neurosci 23(17):6690-6694.
81. Hariri AR, Drabant EM, Munoz KE, Kolachana BS, Mattay VS, Egan MF, et al. 2005. A susceptibility gene for affective disorders and the response of the human amygdala. Arch Gen Psychiatry 62(2):146-152.
82. Hashimoto R, Moriguchi Y, Yamashita F, Mori T, Nemoto K, Okada T, et al. 2008. Dose-dependent effect of the Val66Met polymorphism of the brain-derived neurotrophic factor gene on memory-related hippocampal activity. Neurosci Res 61(4):360-367.
83. Heils A, Teufel A, Petri S, Stober G, Riederer P, Bengel D, et al. 1996. Allelic variation of human serotonin transporter gene expression. J Neurochem 66(6):2621-2624.
84. Heinz A, Braus DF, Smolka MN, Wrase J, Puls I, Hermann D, et al. 2005. Amygdala-prefrontal coupling depends on a genetic variation of the serotonin transporter. Nat Neurosci 8(1):20-21.
85. Henningsson S, Borg J, Lundberg J, Bah J, Lindstrom M, Ryding E, et al. 2009. Genetic variation in brain-derived neurotrophic factor is associated with serotonin transporter but not serotonin-1A receptor availability in men. Biol Psychiatry 66(5):477-485.
86. Hirvonen J, Karlsson H, Kajander J, Lepola A, Markkula J, Rasi-Hakala H, et al. 2008. Decreased brain serotonin 5-HT1A receptor availability in medication-naive patients with major depressive disorder: an in-vivo imaging study using PET and [carbonyl-11C]WAY-100635. Int J Neuropsychopharmacol 11(4):465-476.
87. Honea RA, Meyer-Lindenberg A, Hobbs KB, Pezawas L, Mattay VS, Egan MF, et al. 2008. Is gray matter volume an intermediate phenotype for schizophrenia? A voxel-based morphometry study of patients with schizophrenia and their healthy siblings. Biol Psychiatry 63(5):465-474.
88. Hu XZ, Lipsky RH, Zhu G, Akhtar LA, Taubman J, Greenberg BD, et al. 2006. Serotonin transporter promoter gain-of-function genotypes are linked to obsessive-compulsive disorder. Am J Hum Genet 78(5):815-826.
89. Huang J, Perlis RH, Lee PH, Rush AJ, Fava M, Sachs GS, et al. 2010. Cross-disorder genomewide analysis of schizophrenia, bipolar disorder, and depression. Am J Psychiatry 167(10):1254-1263.
90. Hyman SE. 2008. A glimmer of light for neuropsychiatric disorders. Nature 455(7215):890-893.
91. Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN, et al. 2007. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 27(9):1533-1539.
92. Inoue H, Yamasue H, Tochigi M, Takei K, Suga M, Abe O, et al. 2010. Effect of tryptophan hydroxylase-2 gene variants on amygdalar and hippocampal volumes. Brain Res 1331:51-57.
93. Ising M, Lucae S, Binder EB, Bettecken T, Uhr M, Ripke S, et al. 2009. A genomewide association study points to multiple loci that predict antidepressant drug treatment outcome in depression. Arch Gen Psychiatry 66(9):966-975.
94. Ito H, Halldin C, Farde L. 1999. Localization of 5-HT1A receptors in the living human brain using [carbonyl-11C]WAY-100635: PET with anatomic standardization technique. J Nucl Med 40(1):102-109.
95. Jans LA, Riedel WJ, Markus CR, Blokland A. 2007. Serotonergic vulnerability and depression: assumptions, experimental evidence and implications. Mol Psychiatry 12(6):522-543.
96. Jedema HP, Gianaros PJ, Greer PJ, Kerr DD, Liu S, Higley JD, et al. 2010. Cognitive impact of genetic variation of the serotonin transporter in primates is associated with differences in brain morphology rather than serotonin neurotransmission. Mol Psychiatry 15(5):512-522, 446.
97. Jessen F, Schuhmacher A, von Widdern O, Guttenthaler V, Hofels S, Suliman H, et al. 2009. No association of the Val66Met polymorphism of the brain-derived neurotrophic factor with hippocampal volume in major depression. Psychiatr Genet 19(2):99-101.
98. Kalbitzer J, Frokjaer VG, Erritzoe D, Svarer C, Cumming P, Nielsen FA, et al. 2009. The personality trait openness is related to cerebral 5-HTT levels. Neuroimage 45(2):280-285.
99. Kasper S, McEwen BS. 2008. Neurobiological and clinical effects of the antidepressant tianeptine. CNS Drugs 22(1):15-26.
100. Kato M, Serretti A. 2008. Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Mol Psychiatry 15(5):473-500.
101. Kendler KS, Gatz M, Gardner CO, Pedersen NL. 2006. A Swedish national twin study of lifetime major depression. Am J Psychiatry 163(1):109-114.
102. Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE. 2005. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 62(6):617-627.
103. Kim-Cohen J, Caspi A, Taylor A, Williams B, Newcombe R, Craig IW, et al. 2006. MAOA, maltreatment, and gene-environment interaction predicting children's mental health: new evidence and a meta-analysis. Mol Psychiatry 11(10):903-913.
104. Kim MJ, Whalen PJ. 2009. The structural integrity of an amygdala-prefrontal pathway predicts trait anxiety. J Neurosci 29(37):11614-11618.
105. Koolschijn PC, van Haren NE, Bakker SC, Hoogendoorn ML, Pol HE, Kahn RS. 2009a. Effects of brain-derived neurotrophic factor Val66Met polymorphism on hippocampal volume change in schizophrenia. Hippocampus 20(9):1010-1017.
106. Koolschijn PC, van Haren NE, Lensvelt-Mulders GJ, Hulshoff Pol HE, Kahn RS. 2009b. Brain volume abnormalities in major depressive disorder: a meta-analysis of magnetic resonance imaging studies. Hum Brain Mapp 30(11):3719-3735.
107. Krishnan V, Nestler EJ. 2008. The molecular neurobiology of depression. Nature 455(7215):894-902.
108. Krishnan V, Nestler EJ. 2010. Linking molecules to mood: new insight into the biology of depression. Am J Psychiatry 167(11):1305-1320.
109. Lanzenberger RR, Mitterhauser M, Spindelegger C, Wadsak W, Klein N, Mien LK, et al. 2007. Reduced serotonin-1A receptor binding in social anxiety disorder. Biol Psychiatry 61(9):1081-1089.
110. Lasky-Su JA, Faraone SV, Glatt SJ, Tsuang MT. 2005. Meta-analysis of the association between two polymorphisms in the serotonin transporter gene and affective disorders. Am J Med Genet B Neuropsychiatr Genet 133B(1):110-115.
111. Lee BT, Ham BJ. 2008a. Monoamine oxidase A-uVNTR genotype affects limbic brain activity in response to affective facial stimuli. Neuroreport 19(5):515-519.
112. Lee BT, Ham BJ. 2008b. Serotonergic genes and amygdala activity in response to negative affective facial stimuli in Korean women. Genes Brain Behav 7(8):899-905.
113. Lee M, Bailer UF, Frank GK, Henry SE, Meltzer CC, Price JC, et al. 2005. Relationship of a 5-HT transporter functional polymorphism to 5-HT1A receptor binding in healthy women. Mol Psychiatry 10(8):715-716.
114. Lemonde S, Turecki G, Bakish D, Du L, Hrdina PD, Bown CD, et al. 2003. Impaired repression at a 5-hydroxytryptamine 1A receptor gene polymorphism associated with major depression and suicide. J Neurosci 23(25):8788-8799.
115. Lesch KP, Bengel D, Heils A, Sabol SZ, Greenberg BD, Petri S, et al. 1996. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 274(5292):1527-1531.
116. Licinio J, Dong C, Wong ML. 2009. Novel sequence variations in the brain-derived neurotrophic factor gene and association with major depression and antidepressant treatment response. Arch Gen Psychiatry 66(5):488-497.
117. Lopez-Leon S, Janssens AC, Gonzalez-Zuloeta Ladd AM, Del-Favero J, Claes SJ, Oostra BA, et al. 2008. Meta-analyses of genetic studies on major depressive disorder. Mol Psychiatry 13(8):772-785.
118. Lothe A, Boni C, Costes N, Gorwood P, Bouvard S, Le Bars D, et al. 2009. Association between triallelic polymorphism of the serotonin transporter and [18F]MPPF binding potential at 5-HT1A receptors in healthy subjects. Neuroimage 47(2):482-492.
119. Lu B, Pang PT, Woo NH. 2005. The yin and yang of neurotrophin action. Nat Rev Neurosci 6(8):603-614.
120. Martinowich K, Lu B. 2008. Interaction between BDNF and serotonin: role in mood disorders. Neuropsychopharmacology 33(1):73-83.
121. Matsuo K, Walss-Bass C, Nery FG, Nicoletti MA, Hatch JP, Frey BN, et al. 2009. Neuronal correlates of brain-derived neurotrophic factor Val66Met polymorphism and morphometric abnormalities in bipolar disorder. Neuropsychopharmacology 34(8):1904-1913.
122. Matthews SC, Strigo IA, Simmons AN, Yang TT, Paulus MP. 2008. Decreased functional coupling of the amygdala and supragenual cingulate is related to increased depression in unmedicated individuals with current major depressive disorder. J Affect Disord 111(1):13-20.
123. Mayberg HS, Lozano AM, Voon V, McNeely HE, Seminowicz D, Hamani C, et al. 2005. Deep brain stimulation for treatment-resistant depression. Neuron 45(5):651-660.
124. McMahon FJ, Akula N, Schulze TG, Muglia P, Tozzi F, Detera-Wadleigh SD, et al. 2010. Meta-analysis of genome-wide association data identifies a risk locus for major mood disorders on 3p21.1. Nat Genet 42(2):128-131.
125. Meltzer CC, Price JC, Mathis CA, Butters MA, Ziolko SK, Moses-Kolko E, et al. 2004. Serotonin 1A receptor binding and treatment response in late-life depression. Neuropsychopharmacology 29(12):2258-2265.
126. Meyer-Lindenberg A. 2010. Intermediate or brainless phenotypes for psychiatric research? Psychol Med 40(7):1057-1062.
127. Meyer-Lindenberg A, Weinberger DR. 2006. Intermediate phenotypes and genetic mechanisms of psychiatric disorders. Nat Rev Neurosci 7(10):818-827.
128. Meyer-Lindenberg A, Buckholtz JW, Kolachana B, A RH, Pezawas L, Blasi G, Wabnitz A, et al. 2006. Neural mechanisms of genetic risk for impulsivity and violence in humans. Proc Natl Acad Sci USA 103(16):6269-6274.
129. Meyer JH, Ginovart N, Boovariwala A, Sagrati S, Hussey D, Garcia A, et al. 2006. Elevated monoamine oxidase a levels in the brain: an explanation for the monoamine imbalance of major depression. Arch Gen Psychiatry 63(11):1209-1216.
130. Mickey BJ, Ducci F, Hodgkinson CA, Langenecker SA, Goldman D, Zubieta JK. 2008. Monoamine oxidase A genotype predicts human serotonin 1A receptor availability in vivo. J Neurosci 28(44):11354-11359.
131. Miller G. 2010. Psychiatry. Beyond DSM: seeking a brain-based classification of mental illness. Science 327(5972):1437.
132. Montag C, Reuter M, Newport B, Elger C, Weber B. 2008. The BDNF Val66Met polymorphism affects amygdala activity in response to emotional stimuli: evidence from a genetic imaging study. Neuroimage 42(4):1554-1559.
133. Moses-Kolko EL, Price JC, Thase ME, Meltzer CC, Kupfer DJ, Mathis CA, et al. 2007. Measurement of 5-HT1A receptor binding in depressed adults before and after antidepressant drug treatment using positron emission tomography and [11C] WAY-100635. Synapse 61(7):523-530.
134. Mossner R, Mikova O, Koutsilieri E, Saoud M, Ehlis AC, Muller N, et al. 2007. Consensus paper of the WFSBP Task Force on Biological Markers: biological markers in depression. World J Biol Psychiatry 8(3):141-174.
135. Muglia P, Tozzi F, Galwey NW, Francks C, Upmanyu R, Kong XQ, et al. 2010. Genome-wide association study of recurrent major depressive disorder in two European case-control cohorts. Mol Psychiatry 15(6):589-601.
136. Munafo MR, Brown SM, Hariri AR. 2008. Serotonin transporter (5-HTTLPR) genotype and amygdala activation: a meta-analysis. Biol Psychiatry 63(9):852-857.
137. Munafo MR, Freimer NB, Ng W, Ophoff R, Veijola J, Miettunen J, et al. 2009. 5-HTTLPR genotype and anxiety-related personality traits: a meta-analysis and new data. Am J Med Genet B Neuropsychiatr Genet 150B(2):271-281.
138. Murthy NV, Selvaraj S, Cowen PJ, Bhagwagar Z, Riedel WJ, Peers P, et al. 2010. Serotonin transporter polymorphisms (SLC6A4 insertion/deletion and rs25531) do not affect the availability of 5-HTT to [11C] DASB binding in the living human brain. Neuroimage 52(1):50-54.
139. Neumeister A, Bain E, Nugent AC, Carson RE, Bonne O, Luckenbaugh DA, et al. 2004. Reduced serotonin type 1A receptor binding in panic disorder. J Neurosci 24(3):589-591.
140. Neuner I, Kellermann T, Stocker T, Kircher T, Habel U, Shah JN, et al. 2010. Amygdala hypersensitivity in response to emotional faces in Tourette's patients. World J Biol Psychiatry 11(7):858-872.
141. Nordanskog P, Dahlstrand U, Larsson MR, Larsson EM, Knutsson L, Johanson A. 2010. Increase in hippocampal volume after electroconvulsive therapy in patients with depression: a volumetric magnetic resonance imaging study. J ECT 26(1):62-67.
142. Noskova T, Pivac N, Nedic G, Kazantseva A, Gaysina D, Faskhutdinova G, et al. 2008. Ethnic differences in the serotonin transporter polymorphism (5-HTTLPR) in several European populations. Prog Neuropsychopharmacol Biol Psychiatry 32(7):1735-1739.
143. Pacheco J, Beevers CG, Benavides C, McGeary J, Stice E, Schnyer DM. 2009. Frontal-limbic white matter pathway associations with the serotonin transporter gene promoter region (5-HTTLPR) polymorphism. J Neurosci 29(19):6229-6233.
144. Parsey RV, Oquendo MA, Ogden RT, Olvet DM, Simpson N, Huang YY, et al. 2006. Altered serotonin 1A binding in major depression: a [carbonyl-C-11] WAY100635 positron emission tomography study. Biol Psychiatry 59(2):106-113.
145. Pezawas L, Meyer-Lindenberg A. 2010. Imaging genetics: Progressing by leaps and bounds. Neuroimage 53(3):801-803.
146. Pezawas L, Verchinski BA, Mattay VS, Callicott JH, Kolachana BS, Straub RE, et al. 2004. The brain-derived neurotrophic factor val66met polymorphism and variation in human cortical morphology. J Neurosci 24(45):10099-10102.
147. Pezawas L, Meyer-Lindenberg A, Drabant EM, Verchinski BA, Munoz KE, Kolachana BS, et al. 2005. 5-HTTLPR polymorphism impacts human cingulate-amygdala interactions: a genetic susceptibility mechanism for depression. Nat Neurosci 8(6):828-834.
148. Pezawas L, Meyer-Lindenberg A, Goldman AL, Verchinski BA, Chen G, Kolachana BS, et al. 2008. Evidence of biologic epistasis between BDNF and SLC6A4 and implications for depression. Mol Psychiatry 13(7):709-716.
149. Praschak-Rieder N, Kennedy J, Wilson AA, Hussey D, Boovariwala A, Willeit M, et al. 2007. Novel 5-HTTLPR allele associates with higher serotonin transporter binding in putamen: a [(11)C] DASB positron emission tomography study. Biol Psychiatry 62(4):327-331.
150. Price JL, Drevets WC. 2010. Neurocircuitry of mood disorders. Neuropsychopharmacology 35(1):192-216.
151. Rao H, Gillihan SJ, Wang J, Korczykowski M, Sankoorikal GM, Kaercher KA, et al. 2007. Genetic variation in serotonin transporter alters resting brain function in healthy individuals. Biol Psychiatry 62(6):600-606.
152. Rao U, Chen LA, Bidesi AS, Shad MU, Thomas MA, Hammen CL. 2009. Hippocampal changes associated with early-life adversity and vulnerability to depression. Biol Psychiatry 67(4):357-364.
153. Reimold M, Smolka MN, Schumann G, Zimmer A, Wrase J, Mann K, et al. 2007. Midbrain serotonin transporter binding potential measured with [11C]DASB is affected by serotonin transporter genotype. J Neural Transm 114(5):635-639.
154. Riccio O, Potter G, Walzer C, Vallet P, Szabo G, Vutskits L, et al. 2009. Excess of serotonin affects embryonic interneuron migration through activation of the serotonin receptor 6. Mol Psychiatry 14(3):280-290.
155. Richardson-Jones JW, Craige CP, Guiard BP, Stephen A, Metzger KL, Kung HF, et al. 2010. 5-HT1A autoreceptor levels determine vulnerability to stress and response to antidepressants. Neuron 65(1):40-52.
156. Risch N, Herrell R, Lehner T, Liang KY, Eaves L, Hoh J, et al. 2009. Interaction between the serotonin transporter gene (5-HTTLPR), stressful life events, and risk of depression: a meta-analysis. J Am Med Assoc 301(23):2462-2471.
157. Sabol SZ, Hu S, Hamer D. 1998. A functional polymorphism in the monoamine oxidase A gene promoter. Hum Genet 103(3):273-279.
158. Saijo T, Takano A, Suhara T, Arakawa R, Okumura M, Ichimiya T, et al. 2010. Effect of electroconvulsive therapy on 5-HT1A receptor binding in patients with depression: a PET study with [11C] WAY 100635. Int J Neuropsychopharmacol 13(6):785-791.
159. Sargent PA, Kjaer KH, Bench CJ, Rabiner EA, Messa C, Meyer J, et al. 2000. Brain serotonin1A receptor binding measured by positron emission
160. Scheuch K, Lautenschlager M, Grohmann M, Stahlberg S, Kirchheiner J, Zill P, et al. 2007. Characterization of a functional promoter polymorphism of the human tryptophan hydroxylase 2 gene in serotonergic raphe neurons. Biol Psychiatry 62(11):1288-1294.
161. Schlaepfer TE, George MS, Mayberg H. 2010. WFSBP Guidelines on brain stimulation treatments in psychiatry. World J Biol Psychiatry 11(1):2-18.
162. Schofield PR, Williams LM, Paul RH, Gatt JM, Brown K, Luty A, et al. 2009. Disturbances in selective information processing associated with the BDNF Val66Met polymorphism: evidence from cognition, the P300 and fronto-hippocampal systems. Biol Psychol 80(2):176-188.
163. Schosser A, Kasper S. 2009. The role of pharmacogenetics in the treatment of depression and anxiety disorders. Int Clin Psychopharmacol 24(6):277-288.
164. Schulze TG, Muller DJ, Krauss H, Scherk H, Ohlraun S, Syagailo YV, et al. 2000. Association between a functional polymorphism in the monoamine oxidase A gene promoter and major depressive disorder. Am J Med Genet 96(6):801-803.
165. Serretti A, Kato M, De Ronchi D, Kinoshita T. 2007. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients. Mol Psychiatry 12(3):247-257.
166. Sharp T, Boothman L, Raley J, Queree P. 2007. Important messages in the 'post': recent discoveries in 5-HT neurone feedback control. Trends Pharmacol Sci 28(12):629-636.
167. Sheline YI, Barch DM, Donnelly JM, Ollinger JM, Snyder AZ, Mintun MA. 2001. Increased amygdala response to masked emotional faces in depressed subjects resolves with antidepressant treatment: an fMRI study. Biol Psychiatry 50(9):651-658.
168. Shi J, Potash JB, Knowles JA, Weissman MM, Coryell W, Scheftner WA, et al. 2011. Genome-wide association study of recurrent early-onset major depressive disorder. Mol Psychiatry 16(2):193-201.
169. Shyn SI, Shi J, Kraft JB, Potash JB, Knowles JA, Weissman MM. 2009. Novel loci for major depression identified by genome-wide association study of Sequenced Treatment Alternatives to Relieve Depression and meta-analysis of three studies. Mol Psychiatry 16(2):202-215.
170. Siegle GJ, Steinhauer SR, Thase ME, Stenger VA, Carter CS. 2002. Can't shake that feeling: event-related fMRI assessment of sustained amygdala activity in response to emotional information in depressed individuals. Biol Psychiatry 51(9):693-707.
171. Smolka MN, Buhler M, Schumann G, Klein S, Hu XZ, Moayer M, et al. 2007. Gene-gene effects on central processing of aversive stimuli. Mol Psychiatry 12(3):307-317.
172. Spindelegger C, Lanzenberger R, Wadsak W, Mien LK, Stein P, Mitterhauser M, et al. 2009. Influence of escitalopram treatment on 5-HT 1A receptor binding in limbic regions in patients with anxiety disorders. Mol Psychiatry 14(11):1040-1050.
173. Stein JL, Wiedholz LM, Bassett DS, Weinberger DR, Zink CF, Mattay VS, et al. 2007. A validated network of effective amygdala connectivity. Neuroimage 36(3):736-745.
174. Strigo IA, Simmons AN, Matthews SC, Craig AD, Paulus MP. 2008. Association of major depressive disorder with altered functional brain response during anticipation and processing of heat pain. Arch Gen Psychiatry 65(11):1275-1284.
175. Strobel A, Gutknecht L, Rothe C, Reif A, Mossner R, Zeng Y, et al. 2003. Allelic variation in 5-HT1A receptor expression is associated with anxiety- and depression-related personality traits. J Neural Transm 110(12):1445-1453.
176. Sullivan PF, Neale MC, Kendler KS. 2000. Genetic epidemiology of major depression: review and meta-analysis. Am J Psychiatry 157(10):1552-1562.
177. Surguladze SA, Elkin A, Ecker C, Kalidindi S, Corsico A, Giampietro V, et al. 2008. Genetic variation in the serotonin transporter modulates neural system-wide response to fearful faces. Genes Brain Behav 7(5):543-551.
178. Surtees PG, Wainwright NW, Willis-Owen SA, Luben R, Day NE, Flint J. 2006. Social adversity, the serotonin transporter (5-HTTLPR) polymorphism and major depressive disorder. Biol Psychiatry 59(3):224-229.
179. Suslow T, Konrad C, Kugel H, Rumstadt D, Zwitserlood P, Schoning S, et al. 2010. Automatic mood-congruent amygdala responses to masked facial expressions in major depression. Biol Psychiatry 67(2):155-160.
180. Szeszko PR, Lipsky R, Mentschel C, Robinson D, Gunduz-Bruce H, Sevy S, et al. 2005. Brain-derived neurotrophic factor val66met polymorphism and volume of the hippocampal formation. Mol Psychiatry 10(7):631-636.
181. Taylor MJ, Sen S, Bhagwagar Z. 2010. Antidepressant response and the serotonin transporter gene-linked polymorphic region. Biol Psychiatry 68(6):536-543.
182. Uher R, McGuffin P. 2010. The moderation by the serotonin transporter gene of environmental adversity in the etiology of depression: 2009 update. Mol Psychiatry 15(1):18-22
183. Uher R, Perroud N, Ng MY, Hauser J, Henigsberg N, Maier W, et al. 2010. Genome-wide pharmacogenetics of antidepressant response in the GENDEP project. Am J Psychiatry 167(5):555-564.
184. van Praag HM, Kahn RS, Asnis GM, Wetzler S, Brown SL, Bleich A, et al. . 1987. Denosologization of biological psychiatry or the specificity of 5-HT disturbances in psychiatric disorders. J Affect Disord 13(1):1-8.
185. van Tol MJ, van der Wee NJ, van den Heuvel OA, Nielen MM, Demenescu LR, Aleman A, et al. 2010. Regional brain volume in depression and anxiety disorders. Arch Gen Psychiatry 67(10):1002-1011.
186. Varnas K, Halldin C, Hall H. 2004. Autoradiographic distribution of serotonin transporters and receptor subtypes in human brain. Hum Brain Mapp 22(3):246-260.
187. Verhagen M, van der Meij A, van Deurzen PA, Janzing JG, Arias-Vasquez A, Buitelaar JK, et al. 2010. Meta-analysis of the BDNF Val66Met polymorphism in major depressive disorder: effects of gender and ethnicity. Mol Psychiatry 15(3):260-271.
188. Videbech P, Ravnkilde B. 2004. Hippocampal volume and depression: a meta-analysis of MRI studies. Am J Psychiatry 161(11):1957-1966.
189. Viviani R, Sim EJ, Lo H, Beschoner P, Osterfeld N, Maier C, et al. 2010. Baseline brain perfusion and the serotonin transporter promoter polymorphism. Biol Psychiatry 67(4):317-322.
190. Walther DJ, Peter JU, Bashammakh S, Hortnagl H, Voits M, Fink H, et al. 2003. Synthesis of serotonin by a second tryptophan hydroxylase isoform. Science 299(5603):76.
191. Williams LM, Gatt JM, Schofield PR, Olivieri G, Peduto A, Gordon E. 2009. ' Negativity bias ' in risk for depression and anxiety: brain-body fear circuitry correlates, 5-HTT-LPR and early life stress. Neuroimage 47(3):804-814.
192. Willis-Owen SA, Turri MG, Munafo MR, Surtees PG, Wainwright NW, Brixey RD, et al. 2005. The serotonin transporter length polymorphism, neuroticism, and depression: a comprehensive assessment of association. Biol Psychiatry 58(6):451-456.
193. Windischberger C, Lanzenberger R, Holik A, Spindelegger C, Stein P, Moser U, et al. 2009. Area-specific modulation of neural activation comparing escitalopram and citalopram revealed by pharmaco-fMRI: a randomized cross-over study. Neuroimage 49(2):1161-1170.
194. Yu YW, Tsai SJ, Hong CJ, Chen TJ, Chen MC, Yang CW. 2005. Association study of a monoamine oxidase a gene pro moter polymorphism with major depressive disorder and antidepressant response. Neuropsychopharmacology 30(9):1719-1723.
195. Zhang X, Beaulieu JM, Sotnikova TD, Gainetdinov RR, Caron MG. 2004. Tryptophan hydroxylase-2 controls brain serotonin synthesis. Science 305(5681):217.
196. Zhang X, Gainetdinov RR, Beaulieu JM, Sotnikova TD, Burch LH, Williams RB, et al. 2005. Loss-of-function mutation in tryptophan hydroxylase-2 identified in unipolar major depression. Neuron 45(1):11-16.
197. Zhou Z, Roy A, Lipsky R, Kuchipudi K, Zhu G, Taubman J, et al. 2005. Haplotype-based linkage of tryptophan hydroxylase 2 to suicide attempt, major depression, and cerebrospinal fluid 5-hydroxyindoleacetic acid in 4 populations. Arch Gen Psychiatry 62(10):1109-1118.